RenovoRx Revenue Surges 61% as RenovoCath Expands Beyond Pancreatic Cancer
Event summary
- RenovoRx reported $909,000 in Q2 2026 revenue, up 61% sequentially and 115% year-over-year.
- The company raised its annual revenue guidance to $3.75M–$4.25M from $3M–$4M.
- RenovoCath was used for the first time in a sarcoma patient, expanding beyond pancreatic cancer.
- Phase III TIGeR-PaC trial reached full enrollment; topline data expected in H2 2027.
The big picture
RenovoRx is capitalizing on accelerating commercial adoption of its RenovoCath device, with revenue growth outpacing expectations. The expansion into new cancer indications signals a strategic shift toward broader oncology applications, while the Phase III trial completion sets the stage for potential regulatory milestones. The company’s ability to maintain this momentum will be critical as it approaches cash-flow break-even in late 2027.
What we're watching
- Commercial Momentum
- Whether RenovoRx can sustain its rapid revenue growth and expand its customer base beyond the current 21 active cancer centers.
- Clinical Expansion
- How quickly RenovoCath adoption spreads to other solid tumors, following its first use in sarcoma.
- Trial Outcomes
- The impact of the TIGeR-PaC trial results on RenovoRx’s long-term strategy and potential regulatory approvals.
Related topics